The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
Launched by WUHAN UNION HOSPITAL, CHINA · Oct 17, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with sq-NSCLC;
- • Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
- • ≥ 18 years and ≤ 80 years old;
- • No previous treatment in the lungs or any other organ.
- Exclusion Criteria:
- • History of cancer treatment;
- • History of other malignant tumors;
- • Irregular treatment or poor compliance;
- • Incomplete clinical information or lost to follow-up.
About Wuhan Union Hospital, China
Wuhan Union Hospital, affiliated with Huazhong University of Science and Technology, is a leading medical institution located in Wuhan, China. Renowned for its comprehensive healthcare services and advanced research capabilities, the hospital plays a pivotal role in clinical trials aimed at enhancing medical knowledge and patient care. With a commitment to innovation and excellence, Wuhan Union Hospital collaborates with various stakeholders to conduct rigorous and ethically sound clinical research, contributing significantly to the advancement of medical science and public health both domestically and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Xueyun Tan, MD
Study Director
Wuhan Union Hospital, China
Yang Jin, PHD
Principal Investigator
Wuhan Union Hospital, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported